Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer
Phase II Trial of Gemcitabine and Docetaxel in Advanced Carcinoma of the Urothelium
Sponsor: Eastern Cooperative Oncology Group
Listed as NCT00004223, this PHASE2 trial focuses on Bladder Cancer and Transitional Cell Cancer of the Renal Pelvis and Ureter and remains completed. Sponsored by Eastern Cooperative Oncology Group, it has been updated 8 times since 2000, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jul 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2023 [monthly]
Completed PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Feb 2000
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eastern Cooperative Oncology Group
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Albany, United States, Ann Arbor, United States, Atlanta, United States, Baltimore, United States, Boston, United States, Brooklyn, United States, Cedar Rapids, United States, Chicago, United States, Cleveland, United States, Columbus, United States and 48 more location s